ASSESSMENT FOR UNDERLYING ETIOLOGY OF BRONCHIOLOALVEOLAR CARCINOMA (BAC). IMPACTS OF SMOKING HABIT AND EGFR MUTATION

被引：0
|
作者：
Hiramatsu, Miyako [1 ]
Nagano, Hiroko [1 ]
Sato, Seijiro [1 ]
Ninomiya, Hironori [1 ]
Inamura, Kentaro [1 ]
Motoi, Noriko [1 ]
Uehara, Hirofuimi [2 ]
Mun, Mingyon [2 ]
Sakao, Yukinori [2 ]
Okumura, Sakae [2 ]
Shiraishi, Yuji [3 ]
Nakagawa, Ken [2 ]
Ishikawa, Yuichi [1 ]
机构：
[1] Japanese Fdn Canc Res, Dept Pathol, Tokyo, Japan
[2] Canc Inst Hosp, Tokyo, Japan
[3] Fukujuji Hosp, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
EGFR mutation; Smoking; lung adenocarcinoma;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1338 / S1339
页数：2
相关论文
共 13 条
  • [1] Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation
    Taja-Chayeb, L
    Candelaria, M
    Brom, R
    Trejo-Becerril, C
    Meza, F
    Duenas-Gonzalez, A
    [J]. LUNG CANCER, 2005, 50 (02) : 259 - 263
  • [2] EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC):: Results of a prospective phase II trial.
    Miller, V. A.
    Zakowski, M.
    Riely, G. J.
    Pao, W.
    Ladanyi, M.
    Tsao, A. S.
    Sandler, A.
    Herbst, R.
    Kris, M. G.
    Johnson, D. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 364S - 364S
  • [3] KRAS, EGFR and p53 alterations in bronchioloalveolar carcinoma and BAC-predominant adenocarcinoma
    Sica, G.
    Saqi, A.
    Kitabayashi, N.
    Altorki, N.
    Vazquez, M. F.
    Chen, Y. T.
    [J]. MODERN PATHOLOGY, 2007, 20 : 331A - 331A
  • [4] KRAS, EGFR and p53 alterations in bronchioloalveolar carcinoma and BAC-predominant adenocarcinoma
    Sica, G.
    Saqi, A.
    Kitabayashi, N.
    Altorki, N.
    Vazquez, M. F.
    Chen, Y. T.
    [J]. LABORATORY INVESTIGATION, 2007, 87 : 331A - 331A
  • [5] WHAT ARE THE DIFFERENCES BETWEEN BRONCHIOLOALVEOLAR CARCINOMA (BAC) AND ADENOCARCINOMA PATIENTS (P) WITH EGFR MUTATIONS WHEN TREATED WITH ERLOTINIB?
    Reguart, N.
    Cardenal, F.
    Porta, R.
    Provencio, M.
    Gonzalez-Larriba, J. L.
    Pallares, C.
    Massuti, B.
    Insa, A.
    Lopez-Vivanco, G.
    Rosell, R.
    [J]. ANNALS OF ONCOLOGY, 2008, 19 : 99 - 99
  • [6] Identification of epidermal growth factor receptor (EGFR) mutations in adenocarcinoma of the lung with bronchioloalveolar carcinoma (BAC) compound.
    不详
    [J]. VIRCHOWS ARCHIV, 2005, 447 (02) : 172 - 173
  • [7] Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC).
    Kris, MG
    Sandler, A
    Miller, V
    Cespon, M
    Zakowski, M
    Pizzo, B
    Venkatraman, E
    Gomez, J
    Johnson, D
    Carbone, D
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 631S - 631S
  • [8] A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma
    Haneda, H
    Sasaki, H
    Lindeman, N
    Kawano, O
    Endo, K
    Suzuki, E
    Shimizu, S
    Yukiue, H
    Kobayashi, Y
    Yano, M
    Fujii, Y
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (02) : 69 - 75
  • [9] Increased EGFR gene copy number detected by fish is associated with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma (BAC) (S0126).
    Hirsch, FR
    Gandara, DR
    McCoy, J
    Crowley, J
    West, HJ
    Gummerlock, PH
    Bunn, PA
    Franklin, WA
    Varella-Garcia, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 628S - 628S
  • [10] Long-lasting complete remission with tyrosine kinase inhibitor in bronchioloalveolar carcinoma with a so far unknown EGFR mutation
    Ludovini, Vienna
    Gori, Stefania
    Pistola, Lorenza
    Della Fazia, Maria Agnese
    Piobbico, Danilo
    Servillo, Giuseppe
    Flacco, Antonella
    Seuderi, Cristina
    Crino, Lucio
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 452 - 453
12